Healthcare Journal Warns Young Adults on Cannabis Legalization Risks

Healthcare Industry Raises Red Flag on Youth Cannabis Use

Managed Healthcare Executive, a peer-reviewed journal for health plan decision-makers, issued a public health advisory targeting young adults in states with recent legalization. The timing is deliberate: federal rescheduling momentum and state ballot initiatives are poised to expand legal access to an additional 60 million Americans by 2027. Young adults comprise the highest-uptake demographic in every market studied to date.

The journal's editorial board cited emerging longitudinal data linking frequent cannabis use before age 25 to measurable deficits in executive function, working memory, and attention span. Heavy users show effects that appear dose-dependent and may persist years after they quit.

Brain Development Window Drives Clinical Concern

Neuroscience consensus holds that prefrontal cortex maturation continues through age 25, making this population uniquely vulnerable to THC exposure. The endocannabinoid system plays a documented role in synaptic pruning and white matter development during late adolescence. Disruption of these processes during critical windows may be irreversible.

Managed Healthcare Executive's analysis drew on data from Colorado and Washington, the first adult-use states. Both jurisdictions recorded 40-60% increases in daily or near-daily use among 18-25-year-olds within three years of legalization, compared to 12-18% increases in older cohorts.

Psychosis Link Gains Traction in Medical Literature

A 2025 JAMA Psychiatry meta-analysis linked high-potency cannabis use to a threefold increase in first-episode psychosis risk among users under 25. Products exceeding 15% THC now dominate retail shelves in legal states. Concentrates and vapes routinely test above 70% THC. These potency levels were virtually nonexistent in illicit markets a decade ago.

Emergency department visits for cannabis-induced psychosis in Colorado rose 240% between 2019 and 2025, with the steepest climb in the 18-24 age bracket. Managed Healthcare Executive framed this as a cost-of-care issue for insurers and a quality-of-life issue for patients.

Dependency Rates Climb Post-Legalization

Roughly 10% of adult cannabis users meet DSM-5 criteria for cannabis use disorder, but that rate jumps to 17% among those who begin use before age 18 and 14% for those starting between 18-25. Legalization appears to compress initiation timelines. States with legal markets report a median age of first use dropping from 19.2 years in 2015 to 17.8 years in 2025.

Healthcare systems are seeing more young adults seeking treatment for withdrawal symptoms—irritability, insomnia, and appetite disruption—conditions that were rarely documented in clinical settings prior to widespread high-potency product availability.

Impaired Driving and Academic Performance Flagged

Studies show a 6-8% decline in college GPA among students who transitioned from non-use to weekly or more frequent use. The mechanism appears to involve working memory deficits that compound over semesters. Employers in safety-sensitive industries have also reported upticks in positive drug tests and workplace accidents in states with legal markets.

Traffic fatality data from Washington showed THC-positive drivers involved in fatal crashes rose from 8% in 2013 to 21% in 2024. Drivers under 25 were overrepresented in that cohort. The journal called for expanded public education on impairment thresholds and risks.

Industry Response and Regulatory Gaps

The cannabis industry has historically resisted age-gated marketing restrictions beyond the statutory 21+ floor, arguing that education should replace prohibition. Trade groups like the National Cannabis Industry Association have funded harm-reduction campaigns, but critics argue these efforts are dwarfed by the marketing spend promoting high-THC products.

Managed Healthcare Executive called for mandatory potency caps, clearer labeling on cognitive risks, and insurance coverage for cannabis use disorder treatment. No state has yet implemented a THC ceiling for adult-use products, though Vermont and Connecticut have debated 15% caps.

For full background on this story, see the CannIntel topic hub on youth cannabis health risks.

What Clinicians and Payers Should Watch

Health plans are preparing for a claims spike. That's the cleanest read on this intervention. Mental health and substance abuse treatment costs tied to cannabis are projected to rise 30-50% in newly legal states over the next five years, according to actuarial models cited by the journal.

Clinicians should screen young adult patients for frequency and potency of use, not just binary yes/no consumption. Managed care organizations may begin carve-outs or prior authorization requirements for cannabis-related psychiatric claims if the cost curve steepens.

Watch state legislatures convening in January 2027. They'll face pressure to revisit potency regulations and youth-access enforcement as longitudinal health data from early-legal states matures.